alpha-1-antitrypsin deficiency

You know, most of us will s-think strongly about testing for basic autoimmune abnormalities.

Um, if the patient has, um, a coexistent emphysema, uh, we're gonna look for alpha-1 antitrypsin deficiency.

That's a under-recognized cause of bronchiectasis.

And if the patient has, um, severe extrapulmonary diseases, we're gonna look for immune deficiencies.

He has a history of pancreatitis.

Uh, the radiologist says he has primarily upper lobe bronchiectasis.

Uh, which option is most appropriate here? Would you test for PCD by immunofluorescence? Would you test for alpha-1 deficiency, uh, and refer to a genetic counselor? Test for sweat chloride? Refer for genetic testing? Or test for antibodies, uh, to pneumococcal vaccine and refer to an immunologist? So go ahead and vote.

[upbeat instrumental music] Okay, great.

So Beam, Beam Therapeutics filed suit on September twenty-five in the US District Court for the District of Massachusetts.

It alleges that its former scientist, Emma Wang, secretly co-founded Yoltec in July 2021, while she was still employed at Beam, and where she worked until January 2022, and that Yoltec illegally used Beam trade secrets to fuel its alpha-1 antitrypsin deficiency, AATD, program.

The other defendants are Yoltech's CEO, Jensen Wu, Yoltech itself, and Serafa Bio, a new co that has licensed Yoltech's AATD therapy.

Wang is CTO at Serafa.

So there are some overlaps, right? Yol's product is an LNP delivered base editor that corrects the same mutation as Beam's product.

She says Beam can't connect her alleged data access to any specific Yoltech invention.

I think that could be critical if this goes to trial.

And she says that Yoltech has contemporaneous R&D records tracing its work to develop its AATD therapy.

Those protein levels come ahead of any lung or liver outcome.

From Alpha-1 to COPD.

Connect Biopharma's Rademicobart is an antibody against IL-4 receptor alpha, the receptor Dupixent targets.

Its phase two gave a single dose under the skin during a flare on top of standard care to 159 adults with high blood eosinophils.

What was the diagnosis?

She told me that I had Alpha-1 Antitrypsin Deficiency.

Alpha-1 Antitrypsin Deficiency.

And it's a genetic disorder that can cause emphysema.

Alpha-1 Antitrypsin Deficiency, also known as genetic emphysema.

Here is Dr.

Mark Brantley, a professor emeritus at the University of Florida, with a specialty in pulmonary disease generally and Alpha-1 in particular.

How would you define Alpha-1 Antitrypsin Deficiency?